Exelixis (EXEL) Total Liabilities (2010 - 2026)
Exelixis' (EXEL) quarterly Total Liabilities came in at $657.8 million in Q2 2026, down 6.85% year-on-year from $706.2 million in Q2 2025, and down 3.7% quarter-over-quarter from $683.1 million in Q1 2026.
Exelixis (EXEL) Total Liabilities (2010 - 2026) Analysis & Trends
Exelixis' Total Liabilities history runs 17 years deep, the most recent figure standing at $657.8 million for Q2 2026.
- On a quarterly basis, Total Liabilities fell 6.85% year-over-year to $657.8 million in Q2 2026; TTM through Apr 2026 was $657.8 million, a 6.85% decrease from a year earlier, with the FY2026 full-year figure at $683.1 million, down 2.9% from the prior year.
- Total Liabilities declined to $657.8 million in Q2 2026 per EXEL's latest filing, from $683.1 million in the prior quarter.
- Across five years, Total Liabilities topped out at $706.2 million in Q2 2025 and bottomed at $360.3 million in Q2 2022.
- The 5-year median for Total Liabilities is $653.4 million (2024), against an average of $616.8 million.
- Across the five-year window, Total Liabilities jumped 63.27% in 2023 and retreated 6.85% in 2026, its largest moves.
- Year by year, Total Liabilities stood at $583.1 million in 2022, then rose by 16.36% to $678.4 million in 2023, then rose by 0.95% to $684.9 million in 2024, then retreated by 3.21% to $662.8 million in 2025, then decreased by 0.75% to $657.8 million in 2026.
- Per Business Quant, the three latest EXEL Total Liabilities figures stand at $657.8 million (Q2 2026), $683.1 million (Q1 2026), and $662.8 million (Q4 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 60.46 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 177.22 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 3.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 7.33 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 7.12 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 9.45 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 15.48 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.62 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 753.82 Mn |
| 10 | Exelixis | 14.38 Bn | 13.60 Bn | 590.86 Mn | 657.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 657.85 Mn |
| Jan 2, 2026 | 683.10 Mn |
| Oct 3, 2025 | 662.85 Mn |
| Jul 4, 2025 | 644.55 Mn |
| Apr 4, 2025 | 706.22 Mn |
| Jan 3, 2025 | 703.49 Mn |
| Sep 27, 2024 | 684.86 Mn |
| Jun 28, 2024 | 653.39 Mn |
| Mar 29, 2024 | 675.74 Mn |
| Dec 29, 2023 | 678.45 Mn |
| Sep 29, 2023 | 629.29 Mn |
| Jun 30, 2023 | 614.53 Mn |
| Mar 31, 2023 | 588.22 Mn |
| Dec 30, 2022 | 583.06 Mn |
| Sep 30, 2022 | 469.97 Mn |
| Jul 1, 2022 | 490.14 Mn |
| Apr 1, 2022 | 360.27 Mn |
| Dec 31, 2021 | 405.62 Mn |
| Oct 1, 2021 | 335.29 Mn |
| Jul 2, 2021 | 324.19 Mn |